Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR, NMPA) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease

NCT: NCT05174169 · RECRUITING

NCT IDNCT05174169
StatusRECRUITING
Start Date2022-07-08
Completion2030-03-10

Brief Summary

This Phase II/III trial will evaluate the what kind of chemotherapy to recommend to patients based on the presence or absences of circulating tumor DNA (ctDNA) after surgery for colon cancer.

Frequently Asked Questions

What is Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease?

Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease is a clinical trial registered under NCT05174169. Current status: RECRUITING.

What is the status of NCT05174169?

The current status of NCT05174169 (Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease) is: RECRUITING.

When did Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease start?

Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease started on 2022-07-08.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.

↑